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Nitric oxide (NO) triggers escape reactions in the dorsal periaqueductal gray matter (dPAG), 
a core structure mediating panic-associated response, and decreases the release of BDNF 
in vitro. BDNF mediates the panicolytic effect induced by antidepressant drugs and produces 
these effects per se when injected into the dPAG. Based on these findings, we hypothesize 
that nitric oxide synthase (NOS) inhibitors would have panicolytic properties associated with 
increased BDNF signaling in the dPAG. We observed that the repeated (7 days), but not 
acute (1day), systemic administration of the NOS inhibitor aminoguanidine (AMG; 15 
mg/kg/day) increased the latency to escape from the open arm of the elevated T-maze 
(ETM) and inhibited the number of jumps in hypoxia-induced escape reaction in rats, 
suggesting a panicolytic-like effect. Repeated, but not acute, AMG administration (15mg/kg) 
also decreased nitrite levels and increased TRKB phosphorylation at residues Y706/7 in the 
dPAG. Notwithstanding the lack of AMG effect on total BDNF levels in this structure, the 
microinjection of the TRK antagonist K252a into the dPAG blocked the anti-escape effect of 
this drug in the ETM. Taken together our data suggest that the inhibition of NO production 
by AMG increases the levels of pTRKB, which is required for the panicolytic-like effect 
observed. 
 






















The periaqueductal gray matter (PAG) is a midbrain structure critically associated 
with the expression of escape/flight responses. Chemical or electrical stimulation of the 
dorsal regions of the PAG (dorsolateral and dorsomedial columns) in animals triggers 
escape reactions that have been associated with panic attacks (Depaulis et al., 1992; 
Brandão et al., 2008). In humans, stimulation of the dorsal PAG (dPAG) leads to feelings of 
fear and imminent death (Nashold et al., 1969). As evidenced by Mobbs and colleagues, 
situations of proximal threat increase midbrain activation in, putatively, the PAG area (Mobbs 
et al., 2007, 2010).  
The neuronal nitric oxide synthase (NOS1 or nNOS) enzyme is highly expressed in 
the PAG, especially in its dorsolateral columns (Vincent and Kimura, 1992; Onstott et al., 
1993). Nitric oxide (NO) can freely diffuse across the cell membrane and act as a retrograde 
signaling molecule, facilitating glutamate release in several brain regions (Lonart et al., 
1992; Lawrence and Jarrott, 1993; Guevara-Guzman et al., 1994). Activation of the NMDA 
receptor (NMDAr) by glutamate stimulates NO synthesis through calcium influx (Garthwaite 
et al., 1989), resulting in a positive-feedback response. Injections of NO donors or NMDA-
receptor agonists into the dPAG precipitates escape reactions, while local administration of 
NOS inhibitors or NMDAr antagonists prevents such behaviors (De Oliveira et al., 2001; 
Miguel and Nunes-de-Souza, 2006; Aguiar and Guimarães, 2009). 
Activation of extra-synaptic NMDAr (Vanhoutte and Bading, 2003) or increased 
production of NO (Canossa et al., 2002) inhibit the synthesis/release of brain-derived 
neurotrophic factor (BDNF). BDNF, through activation of tropomyosin-related kinase B 
receptors (TRKB), regulates neuronal maturation (Cohen-Cory, 2002), synaptic 

















been proposed that BDNF is also crucial to the effect of antidepressant drugs (Nibuya et al., 
1995; Russo-Neustadt et al., 1999; Coppell et al., 2003; Duman and Monteggia, 2006; 
Molteni et al., 2006; Castrén et al., 2007; Martinowich and Lu, 2008). According to the 
'neurotrophic hypothesis', antidepressant drugs increase BDNF levels, especially in the 
hippocampus and frontal cortex, resulting in synaptic function strengthening and 
antidepressant/anxiolytic responses  (Duman et al., 1997). Antidepressant drugs such as 
fluoxetine are the first-line treatment for panic disorder patients  (Freire et al., 2014). 
Of importance to the present study, the microinjection of BDNF into the dPAG 
inhibited escape responses induced by electrical stimulation of this structure (Casarotto et 
al., 2010). It also attenuated escape produced by exposure to the open arm of the elevated 
T maze (ETM) (Casarotto et al., 2015), usually interpreted as indicative of a panicolytic-like 
effect (for a full description of this latter test, see Zangrossi and Graeff, 2014) . Moreover, 
chronic treatment with different antidepressants increased BDNF levels in the dPAG, and 
this effect was associated with the anti-escape action of these drugs (Casarotto et al., 2015).  
Based on these findings, we here hypothesized that the inhibition of NOS would 
induce panicolytic-like effect by increasing BDNF signaling in the dPAG. To test this 
hypothesis, we first investigated whether acute or repeated treatment with the NOS inhibitor, 
aminoguanidine (AMG), would inhibit escape behavior in the ETM or induced by hypoxia.  
Next, we evaluated whether systemic AMG changes NO, BDNF or TRKB phosphorylation 
levels in the dPAG. Finally, we checked whether TRKB receptors activation in the dPAG is 























2.1. Animals  
Male Wistar rats weighing 220–250g, housed in groups of 6 were kept on a 12h 
dark/light cycle (lights on at 07:00 h) at 22±1oC, with free access to food and water 
throughout the experiment. The experiments reported in this article were performed in 
compliance with Brazilian Council for Animal Experimentation (CONCEA; protocol number: 
114/2007 and 192/2015), which are based on the US National Institutes of Health guide for 
the care and use of laboratory animals (NIH Publications No. 8023, revised 1978). 
 
2.2. Drugs  
Aminoguanidine hydrochloride (AMG; Sigma-Aldrich, #396494) was dissolved in 
sterile saline and injected intraperitoneally (ip) at 1ml/kg volume. K252a (Sigma-Aldrich, 





2.3.1. Elevated T-maze 
The elevated T-maze (ETM) consisted of three arms of equal dimensions (50cm × 
12cm) elevated 50cm above the floor (Zangrossi and Graeff, 2014). One arm was enclosed 
by 40cm high walls, perpendicular to two opposite open arms surrounded by a 1cm high 
Plexiglas rim. 
Two days before the test the animals were gently handled by the experimenter for 5 

















one of the open arms of the ETM for 30 min, as previously described (Casarotto et al., 2015). 
For this, a wood barrier was temporarily placed at the intersection between the open and 
closed arms. This pre-exposition, by shortening the latencies to withdrawal from the open 
arm during the test, renders the escape task more sensitive to the effects of panicolytic 
drugs.  
The animals were tested in the elevated T-maze 60 min after the last drug or vehicle 
administration. For the avoidance task, each animal was placed at the distal end of the 
enclosed arm of the elevated T-maze facing the intersection of the arms. The time taken by 
the rat to leave this arm with the four paws was recorded (baseline). The same measurement 
was repeated in two subsequent trials (avoidance 1 and 2) at 30s intervals; during which 
animals were placed in a Plexiglas cage where they had been previously habituated. For 
the escape task (performed 30s after avoidance 3), rats were placed at the end of the 
previously pre-exposed open arm and the latency to leave this arm with the four paws was 
recorded in 3 consecutive times (escape 1, 2 and 3) with 30s intertrial intervals. The 
measurements were made by a trained observer blinded to the treatment condition. A cut-
off time of 300s was established for the avoidance and escape latencies. For further details 
of this test, see Zangrossi and Graeff (2014). 
 
2.3.2. Open field 
The open-field test was used to assess whether the drugs used affected the 
locomotion of tested animals. The test was performed in a Plexiglas circular arena (80cm 
diameter), with 40cm high walls. Independent groups of animals were randomly placed in 
the center of the circular arena 1h after the injection for behavioral analysis during 15min. 


















2.3.3. Hypoxia test 
The hypoxia chamber consisted of a roof-sealed Plexiglas cylinder (25cm diameter 
and 35cm height) with a removable rubber floor. A flow valve connected to both an air pump 
and a nitrogen (N2) cylinder was attached to the chamber. Hypoxia (7% O2) was produced 
by N2 administration at a flow rate of 4.5l/min during approximately 270s. The concentrations 
of both O2 and CO2 inside the chamber were monitored throughout the experiment (ML206 
Gas Analyzer, AdInstruments, Bella Vista, NSW, Australia) and scanned online with the 
Power Lab Chart 5 software (AdInstruments, Bella Vista, NSW, Australia). 
The animals randomly closed in the chamber and acclimated under atmospheric air 
(21% O2) for 5 min. For this purpose, room air was flushed into the chamber at 4.5l/min flow 
rate. For the induction of hypoxia, N2 was flushed into the chamber (4.5l/min) for 
approximately 4min, until O2 is reduced to 7%, and maintained for 6min. The animal 
behavior was recorded throughout the experiment by a video camera. The number of 
upward jumps during the hypoxic challenge was recorded and analyzed by a trained 
observer blinded to the treatment condition. This behavior, interpreted as escape attempts 
from the experimental environment, was used as a panic index (for more details on this test, 
see Spiacci et al., 2015). 
 
2.4. Stereotaxic surgery and local drug injection 
The animals tested in experiment 5 were anesthetized with 2,2,2-tribromoethanol 
(250mg/kg, ip) and placed in a stereotaxic frame. A guide cannula made of stainless steel 
(OD 0.6mm) was implanted into the brain aimed at the dPAG. The following coordinates 
from lambda were used (Paxinos and Watson, 2007): AP = 0mm, ML = +1.9mm, DV = -
3.2mm. The guide cannula was fixed to the skull with acrylic resin and two stainless steel 


















At the end of the surgery, all animals received an antibiotic preparation (0.3ml, 
intramuscular, of benzylpenicillin and streptomycin, Pentabiotico Veterinário Pequeno Porte; 
Forte Dodge, Brazil), and flunixin meglumine (0.1ml subcutaneous, Banamine, Schering–
Plough, Brazil) for post-surgery analgesia. The animals were left undisturbed for 5 days after 
the surgery, except for normal handling for cage cleaning. 
For drug microinjection, a dental needle (0.3mm outer diameter) was introduced 
through the guide cannula until its tip was 1mm below the cannula end. A volume of 200nl 
was injected into the dPAG for 60s using a 10ul microsyringe (Hamilton, USA) attached to 
a microinfusion pump (KD Scientific, USA). The displacement of an air bubble inside the 
polyethylene catheters connecting the syringe to the intracerebral needles was used to 
monitor the microinjection. The needle was removed 30s after the injection was finished. To 
confirm the site of injection, after the end of the experiments, all animals were deeply 
anesthetized with 4% chloral hydrate (1ml/100g, ip) and 200nl of fast green dye was injected 
through the guide cannula. The brains were removed and sliced for determination of the 
injection site. Only animals with needle tips inside the dorsolateral PAG were considered for 
the experimental analysis. 
 
2.5. Sample collection and preparation 
 
2.5.1. BDNF assay 
Independent groups of animals were deeply anesthetized with chloral hydrate (4%) 
and the dorsal dPAG dissected out using punching needles (OD 4mm). The samples were 
homogenized in lysis buffer (137mM NaCl; 20mM Tris-HCl; 10% glycerol) containing 

















(0.05%, Sigma Aldrich, USA, S6508). The homogenate was centrifuged (10000 x g) at 4oC 
for 15min and the supernatant collected and stored at -80oC. 
BDNF levels in the dPAG samples were analyzed in duplicate by commercial 
sandwich ELISA kit (Promega, #G7610, USA) according to the manufacturer’s instructions. 
Briefly, following preincubation with monoclonal anti-BDNF antibody and blockade of non-
specific sites, the samples were added to 96-well plates. After the secondary and tertiary 
antibodies, the developed color intensity was read at 450nm and compared to a standard 
recombinant BDNF curve (7.8-500pg/ml). The BDNF concentration was normalized by total 
protein content in each sample. 
 
2.5.2. Western-blotting protocol 
The levels of TRKB and phosphorylated TRKB (pTRKB) were determined by western 
blotting (Saarelainen et al., 2003). Briefly, thirty micrograms of total protein content in each 
sample was separated in acrylamide gel electrophoresis and transferred to a PVDF 
membrane. Following blockade with 5%BSA in TBST (20mM Tris-HCl; 150mM NaCl; 0.1% 
Tween20) the membranes were exposed to anti-pTRK at Tyr706/707 residues (1:1000, Cell 
Signaling, #4621, USA), total TRKB (1:1000, Cell Signaling, #4603, USA) or GAPDH 
(1:2000, Santa Cruz, USA, #sc25778) overnight at 4oC. After washing with TBST, the 
membranes were incubated with secondary HRP-conjugated anti-rabbit IgG (1:2000, Santa 
Cruz, #sc2317, USA). Following washing with TBST and TBS, the membranes were 
incubated with 4-chloronaphtol (4CN, Perkin Elmer, #NEL300001EA, USA) for color 
development. The dried membranes were scanned and the intensity of bands relative to 
pTRKB, TRKB and GAPDH were determined using ImageJ software (NIH, version 1.47, 
USA). TRKB phosphorylation was normalized by total TRKB levels and expressed as 


















2.5.3. Quantification of nitrite concentration in PAG 
Samples from dPAG were homogenized in ice-cold phosphate buffer (pH 7.4; 0.5ml) 
and kept on dark until use (within 5 minutes). Nitrite concentrations were analyzed in 
duplicate through an ozone-based reductive chemiluminescence assay as previously 
described (Feelisch et al., 2002). Briefly, 400ul of dPAG samples were injected in a purge 
vessel, and approximately 8ml triiodide solution (2g potassium iodide and 1.3g iodine 
dissolved in 40ml water with 140ml acetic acid) was added. The triiodide solution reduces 
nitrites to NO, which is purged by ozone gas and detected by NO analyzer (Sievers Model 
280 NO analyzer, Boulder, CO, USA). The data were analyzed using the software OriginLab 
(version 6.1). 
 
2.6. Experimental Procedure 
 
2.6.1. Experiment 1: effect of AMG acute injection in ETM 
The potential panicolytic-like effect of acute AMG treatment was investigate using 
ETM. At day 1, independent groups of experimentally naive rats were pre-exposed to one 
of the open arms as described previously. On the 2nd day, the animals received a single 
administration of  AMG (15, 30 or 60m/kg, ip) or vehicle solution and were tested in the ETM 
1 hour after the drug injection. This dose range was based on preliminary studies from our 
group. 
 
2.6.2. Experiment 2: effect of AMG repeated treatment in the ETM, hypoxia-induced 
escape, and open-field test (OF) 

















induced escape test. Since unspecific motor changes could potentially act as a confounding 
factor for aforementioned tests, thus motor behavior was investigated in the open-field test. 
Independent groups of experimentally naive rats were used for each behavioral test. AMG 
(15, 30 or 60m/kg) or vehicle solution was injected ip once a day for 7 days. All the behavioral 
analysis was conducted 1h after the last injection of AMG or vehicle solution. 
 
2.6.3. Experiment 3: effect of AMG treatment on BDNF levels in the PAG 
In order to investigate if AMG effect could be associated to increased levels of BDNF 
in dPAG, independent groups of experimentally naive animals received daily ip injections of 
AMG (15, 30 or 60mg/kg) or vehicle solution for 1 or 7 days, and dPAG samples were 
collected as described previously 1h after the last injection. 
 
2.6.4. Experiment 4: effect of AMG treatment on pTRKB and nitrite levels in the PAG 
This experiment was conducted in order to confirm that the drug regimen used was 
sufficient to modulate NO production and TRKB activity in dPAG. Independent groups of 
experimentally naive rats received daily ip injections of AMG (15mg/kg) or vehicle solution 
for 1 or 7 days. dPAG samples were collected as described above 1h after the last injection. 
Since no changes were observed in the levels of GAPDH or total TRKB (data not shown), 
the intensity relative to pTRKB were normalized by total TRKB and expressed as percent 
from the control group. 
A separate cohort of animals received daily ip injections of AMG (15mg/kg) or vehicle 
solution for 7 days. On day 6, half of vehicle-treated animals received AMG, therefore the 
following groups were: vehicle, AMG-acute, AMG-repeated. 1h after the last injection, the 


















2.6.5. Experiment 5: effect of intra-dPAG administration of K252a on AMG-induced 
panicolytic-like effect 
To test the possible causal relationship between AMG-induced behavioral effects and 
the changes in pTRKB levels in the dPAG, experimentally naïve animals with a surgically 
implanted cannula aiming at the dPAG were treated ip with AMG (15 mg/kg) or saline for 7 
days and submitted to the ETM 1h after the last injection. On days 1, 4 and 7 the animals 
received intra-dPAG injections of K252a (10 pmol/200nl) or vehicle solution 10 min before 
the ip administration of AMG. The final groups were: vehicle-saline; vehicle-AMG; K252a-
saline; K252a-AMG. 
 
2.7. Statistical Analysis 
Parametric tests were preferred, in general, in order to gain statistical power. 
Exception was made for experiments where there was no homoscedasticity, no normal 
distribution, or the measurement scale was not continuous, in such cases non-parametric 
tests were used. Data obtained in ETM was analyzed by two-way ANOVA, with drug 
treatments and trials as factors, followed by Newman-Keuls' posthoc, when appropriate. 
Specifically, for experiment 5, data was analyzed by multivariate ANOVA (factors: trials, 
systemic treatment, intra-dPAG injection) followed by Newman-Keuls' posthoc. Results 
obtained in the open field and ELISA were analyzed by one-way ANOVA, followed by 
Newman-Keuls' posthoc. Nitrite levels in dPAG and hypoxia-induced escape reactions were 
analyzed by Kruskal-Wallis test, followed by Dunn’s posthoc. Western blotting data was 
analyzed by Mann-Whitney’s test. For all experiments p<0.05 was considered statistically 
significant. SPSS 25.0 and GraphPad Prism 6 software were used for statistical analysis 
and graphical representation of the data. All images used in the present study (TIF files), as 





















3.1. Experiment 1: effect of AMG acute injection on elevated T maze (ETM) 
The two-way repeated measures ANOVA of avoidance data showed a significant 
effect of trials [F(2,29)= 42.45; p<0.05], but not of treatment [F(3,29)= 0.36; NS] or interaction 
between these factors [F(6,29)= 0.38; NS] (Fig 1). No effect of trials [F(2,29)= 0.17; NS], 
treatment [F(3,29)= 0.49; NS] or interaction [F(6,29)= 0.22; NS] were found for escape 
latencies, as seen in figure 2a, after acute treatment. 
 
 
Figure 1. Effect of acute (left) or repeated treatment (right) with aminoguanidine (amg) 
in the ETM. Animals received i.p. injections of amg 15, 30 or 60 mg/kg for 1 day (a:  
n=8,8,8,9) or 7 days (b: n=11/group) and the effect upon avoidance latency in ETM was 





















Figure 2. Repeated treatment with aminoguanidine (amg) induces panicolytic-like 
effect in the ETM and hypoxia test. Effect of amg after 1 day (a:  n=8,8,8,9) or 7 days 
treatment (b: n=11/group) on escape latency in ETM, and in the hypoxia-induced escape 
reaction (c: n=7,8,8,8). Columns represent mean ± SEM; two-way ANOVA (a, b) followed 
by Newman-Keuls’ multiple comparison test (when applicable) or Kruskal-Wallis test (c), 
*p˂0.05 vs vehicle-treated group at the same trial. 
 
3.2. Experiment 2: effect of AMG repeated treatment on the ETM, open field and 
hypoxia-induced escape 
The analysis of avoidance data showed a significant effect of trials [F(2,24)= 57.94; 
p<0.05], but no effect of treatment [F(3,24)= 0.72; NS] or interaction between these factors 
[F(6,24)= 1.14; NS], as shown in figure 1b. On the other hand, the analysis of escape 
latencies data (fig. 2b) revealed a significant effect of treatment [F(3,24)= 3.63; p<0.05], 
without effects of trials [F(2,24)= 2.79; NS] or interaction between these factors [F(6,24)= 
0.89; NS]. The posthoc test showed that AMG at 15 and 60 mg/kg significantly increased 
the latency to leave the open arm (Newman-Keuls, p<0.05). For additional experiments, the 
lower effective dose of 15mg/kg was chosen. 
AMG treatment did not induce locomotor changes in the open field test (F(3,24)= 

















22.61±6.73(6); AMG 15mg: 21.09±4.63(7); AMG 30mg: 22.38±5.68(6) and AMG 60mg: 
19.63±0.86(6). 
The Kruskal-Wallis test showed a significant effect of AMG treatment in the hypoxia 
test [H= 7.82; p= 0.04] (fig. 2c). AMG 15mg/kg reduced the number of jumps compared to 
the vehicle-treated group (Dunn’s p<0.05). 
 
3.3.  Experiment 3: effect of AMG treatment on BDNF levels in the PAG 
One-way ANOVA revealed that neither acute [F(3,19)= 0.96; NS] nor repeated 
treatment with AMG [F(3,39)= 0.34; NS] significantly changed BDNF levels in the dPAG, 
(table 1). 
 
Table 1. Effect of acute and repeated treatment with aminoguanidine (15, 30, 60 mg/kg i.p.) 





Acute treatment   
vehicle 100±14.5 100±12.3 
amg 15 103±14.5 134±26.2 
amg 30 77±8.7 - 
amg 60 88±10.4 - 
   
Repeated treatment   
vehicle 100±13.9 100±10.3 
amg 15 109±10.0 92.0±10.0 
amg 30 93±13.8 - 
amg 60 104±7.6 - 
BDNF and TRKB levels are expressed as percentage of the vehicle group. TRKB levels 
were not assessed in amg 30 and amg 60 groups. No significant difference was found by 


















3.4. Experiment 4: effect of AMG treatment on pTRKB and nitrite levels in the PAG 
As shown in figure 3a, Mann-Whitney's U test indicates no significant effect of acute 
treatment with AMG on pTRKB/TRKB levels [U= 7.00; p= 0.18] in the dPAG. On the other 
hand, a significant effect on pTRKB/TRKB levels [U= 2.00; p= 0.03] was observed after 
repeated drug treatment (fig. 3b). Regarding nitrite levels in the dPAG, AMG decreased its 
levels after repeated but not acute administration (fig. 3c), as indicated by Kruskal-Wallis 
[H= 6.33; p= 0.04], followed by Dunn’s multiple comparison test. 
 
 
Figure 3. Repeated but not acute treatment with aminoguanidine increases phospho 
TRKB and decreases nitrite levels in dPAG. Effect of aminoguanidine (15mg/kg, ip) acute 
(a; n= 5,6) or repeated treatment (b; n= 5/group) on TRKB phosphorylation and nitrite levels 
(c; n= 11,10,9) in the dPAG. TRKB phosphorylation was normalized by total TRKB levels 
and expressed as percentage of control (vehicle-treated). Columns represent mean ± SEM; 
Mann-Whitney (a,b) or Kruskal-Wallis followed by Dunn’s multiple comparison test (c), 
*p˂0.05 vs vehicle-treated group.  
 


















As shown in figure 4b, the MANOVA showed a significant interaction between the 
systemic injection of AMG, central administration of K252a and trials [F(1,17)= 5.40, p<0.05] 
on the escape behavior in ETM. The post-hoc test showed that in escape 3 the animals in 
the group vehicle-AMG had longer escape latency when compared to all other groups 
[F(1,17) = 8.25; Newman-Keuls, p<0.05]. Regarding avoidance (fig. 4a), there was a 
significant effect of trials [F(1,17)= 25.9, p<0.05], but no effect of systemic AMG [F(1,17)= 
0.66, NS] or K252a intra-dPAG [F(1,17)= 2.30, NS]. Also, there was no interaction between 
the three factors [F(1,17)= 1.08, NS]. In this experiment, panicolytic-like effect of AMG 
appears in escape 3 but not in escape 1 and 2, which differs from what was observed with 
the experiment presented in figure 1b. The reason for this discrepancy is no clear but may 
be due to a confounding effect of cannulation as an extra variable present in last experiment 
but not in the first one. 
 
Figure 4. Aminoguanidine-induced panicolytic effect is abolished by the TRKB 
antagonist K252a. Effect of aminoguanidine (15 mg/kg i.p.) repeated treatment (7 days) 
and intermittent intra-dPAG injection of K252a (10 pmol/200nl, injected at days 1, 4, 7) on 
avoidance (a) and escape (b) latencies in ETM (n= 6,5,5,5). Avoidance (a) and escape (b) 
latencies were expressed as mean ± SEM; two-way repeated measures ANOVA, *p<0.05 



















The present study investigated the effect of the non-selective NO synthase inhibitor 
AMG on the escape response of rats submitted to the ETM and hypoxia tests, and the 
involvement of TRKB signaling in the AMG-induced effects.  
Aminoguanidine is considered a preferential inhibitor of the inducible isoform of NOS 
(iNOS or NOS2). However, AMG selectivity for iNOS over nNOS is only 4.7 fold (Wolff et 
al., 1997). Due to the higher basal expression of nNOS compared to iNOS (Vincent and 
Kimura, 1992; Onstott et al., 1993), especially in the dPAG, it is very unlikely that in our 
experimental conditions AMG is acting significantly upon iNOS. We were not able to detect 
iNOS in dPAG of naïve male rats by immunofluorescence (data not shown). Additionally, 
raw expression values for nNOS and iNOS, obtained from in-situ hybridization experiments 
scanning the whole brain of mouse through sagittal sections, were extracted from Allen Brain 
Atlas Data Portal (Lein et al., 2007) and compared. Values for iNOS were close to 
noise/undetectable in general (raw value range is 0.05-0.56, lowest and highest values were 
from cortical subplate and olfactory areas, respectively), raw signal from midbrain area was 
0.2. Expression of nNOS was substantial, as expected, and lower and highest raw values 
were obtained for thalamus (1.13) and cortical subplate (5.2), respectively. We also 
compared nNOS and iNOS expression using Expression Atlas from EMBL-EBI 
(Papatheodorou et al., 2018) which provides data from RNAseq experiments, and we 
obtained similar results: nNOS and iNOS average expression in whole brain (in TPM, 
transcripts per million), respectively, were 27.25 and 0.82. Considering all those pieces of 
information, our perspective is that aminoguanidine would preferentially inhibit iNOS in a 
situation where both isoforms are expressed in similar levels (which is the case for the 
studies that stablished the selectivity of this drug in vitro). However, in experimental 
conditions where iNOS is hardly expressed we would expect that nNOS would be the 

















AMG inhibited escape response both in the hypoxia test and in ETM. In the hypoxia 
test, repeated treatment with three doses of AMG decreased escape expression. The effect, 
however, only reached statistical significance with the lowest dose. The hypoxia test is 
based on the idea that panic-attacks are a result of a misinterpreted sensation of suffocation, 
as proposed by Donald Klein (Klein, 1993). In a recent study, Spiacci and colleagues 
described the role of the dPAG area in mediating escape responses (jumps) induced by 
hypoxia exposure. In the same way of our results with repeated AMG treatment, these 
responses were attenuated by high potency benzodiazepines (alprazolam) or repeated 
treatment with fluoxetine (Spiacci et al., 2015).  
In the ETM, repeated but not acute treatment with AMG 15 or 60 mg/kg induced an 
evident anti-escape effect, which was not observed with 30 mg/kg. The reason for the 
inefficacy of this intermediate dose is not clear, but similar U- or bell-shaped curves for the 
effect of NOS inhibitors are not uncommon (Calixto et al., 2008; Lisboa et al., 2013). The 
frequency of such ‘U-shaped’ and the hormetic model has been revised by Calabrese and 
Baldwin (Calabrese and Baldwin, 2003a, 2003b), and appears to be more common than 
acknowledged. However, little is known about the molecular mechanisms behind these 
observations (Rozman and Doull, 2003). It has been proposed that under a challenge (for 
example, drug treatment) several modifications would be triggered in the nervous system to 
counteract the problem. However, if the given challenge is too mild (eg. drug treatment with 
low doses), the counteracting response would not be triggered thus allowing the drug 
effectiveness. On the other hand, if the challenge is too harsh (eg. higher doses) it will 
exceed the counteracting response, allowing the drug effectiveness once again. In this 
scenario, an intermediate dose (enough to trigger the counteracting response but not to 
surpass it) would result in the inefficacy of the treatment.  

















LTE escape response is that AMG systemically delivered would differentially affect distinct 
brains areas, depending on the dose used. Despite the nitrite data implicates NOS inhibition 
in dPAG, it is not possible to rule out AMG-induced NO inhibition in other brain areas, 
especially at higher doses. This possibility should be investigated in further studies.  
Similar to what we have observed with AMG, several clinically used 
antidepressive/panicolytic drugs, such as fluoxetine, imipramine and escitalopram, 
decrease escape expression in the ETM. Some of them (e.g imipramine and escitalopram) 
also impair inhibitory avoidance acquisition, indicating an anxiolytic effect (Pinheiro et al., 
2007, Zangrossi and Graeff, 2014). Under the experimental conditions of the present study, 
however, neither acute nor repeated treatment with AMG was effective regarding this 
parameter.  
Prior studies have investigated the effects of NOS inhibitors in the ETM, but as far as 
we know, there are no other studies examining the effects of the repeated treatment with 
these drugs.  In agreement with our data, no panicolytic-like effect was observed on escape 
behavior after a single injection of the NOS inhibitor L-NAME, either i.p. or intra-dlPAG. 
However, an anxiolytic-like effect on avoidance response was observed by both i.p. or intra-
dlPAG injections (Calixto et al., 2001, 2008). The reason for this discrepancy is not clear but 
it may conceivably reflect the differences in selectivity for the NOS isoforms between AMG 
and L-NAME. L-NAME systemically delivered induced a significant increase in the blood 
pressure which indicates an effect upon endothelial NOS isoform. In fact, as described by 
Boer and colleagues (Boer et al., 2000), AMG is 5- or 6-times more selective for nNOS or 
iNOS, respectively, than for eNOS. In the same study, the authors observed that L-NAME 
exhibit no selectivity between nNOS and eNOS isoforms.  
Behavioral changes induced by NOS inhibitors have been described after acute and 

















induce antidepressant-like effect in the forced swimming test after a single injection in mice 
(Harkin et al., 1999) while repeated treatment is required to observe similar effects in the 
chronic mild stress or learned-helplessness models (Yazir et al., 2012; Stanquini et al., 
2017). A similar profile has been described for classical antidepressant drugs and there is 
evidence that different molecular mechanisms might be engaged in the effects induced by 
acute and repeated treatment (Medrihan et al., 2017). In the ETM, single injections were 
ineffective and  repeated treatment is required for the anxiolytic and panicolytic effect 
induced by classical antidepressants (Teixeira et al., 2000; Poltronieri et al., 2003; Pinheiro 
et al., 2007). It has been proposed that the long-term effect of classical antidepressants 
involves complex neuroplastic alterations in the central nervous system mediated by BDNF-
TRKB signaling (Karpova et al., 2011). Following these findings, we hypothesized that 
regulation of neuronal plasticity might also be required for the long-term antidepressant- and 
anxiolytic/panicolytic-like effects of NOS inhibitors. 
In the proposed scenario, the panicolytic effect of AMG in the ETM and hypoxia test 
could involve the activation of TRKB receptors in the dPAG. Recently, our group described 
the involvement of  for BDNF signaling in this region in the panicolytic-like effects caused by 
antidepressants (Casarotto et al., 2015). Several antidepressant drugs, with anxiolytic and 
panicolytic properties, such as fluoxetine, increase the levels of pTRKB following acute or 
short-term treatment regimen in the hippocampus and prefrontal cortex [for review see 
(Castrén, 2014)]. In previous study we reported that pTRKB and BDNF levels were found 
elevated in the dPAG of imipramine-, but not fluoxetine-treated animals, after 3 days of drug 
administration. The differential effect between these compounds on pTRKB levels was also 
reflected on behavioral results. Only imipramine exerted panicolytic-like effect in the ETM 
following this short-term regimen. Both drugs increased pTRKB levels in the dPAG after 21 

















point (Pinheiro et al., 2007). The microinjection of BDNF into the dPAG increased the escape 
latency in the ETM (Casarotto et al., 2015) without causing any changes in the avoidance 
task, and this neurotrophin also inhibited the escape response induced by electrical 
stimulation of dPAG (Casarotto et al., 2010).  
 Prior studies reported an increase in BDNF levels in the hippocampus in vivo 
following repeated treatment with NOS inhibitors, such as 7NI (Stanquini et al., 2017) and 
aminoguanidine (Beheshti et al, 2019). However, we did not find any change in BDNF levels 
in dPAG after AMG treatment. Despite the difference in the brain area investigated 
(hippocampus versus dPAG), there are other important variances in the experimental 
protocols that could explain the discrepancies. Beheshti and colleagues (2019) reported that 
aminoguanidine was able to modulate hippocampal BDNF levels but the effect of 
aminoguanidine was assessed only in LPS-treated animals, the effect of aminoguanidine 
per se was not investigated. Additionally, in that study LPS effects were found to be 
associated to modulation of inflammatory markers, such as IL-6, IL-10 and TNF-α in 
hippocampus, which strongly indicates LPS induction of iNOS expression by microglia. 
Additionally, only high doses of aminoguanidine were reported to be effective in reduce NO 
production (100-150 mg/kg, which is 10 times higher than the dose found effective in our 
study), which is consisted with LPS-induced iNOS expression. Altogether, the data suggests 
that aminoguanidine effects in Beheshti’s study are most likely mediated by iNOS inhibition, 
while in our study it seems to be mediated by nNOS inhibition. The kinetics of NO production 
differs among NOS isoforms: nNOS activation is short-lived and tightly controlled by calcium 
fluctuations and produces NO in picomolar range concentration, while iNOS-derived NO 
production can be sustained for a long time since it does not dependent on calcium waves 
- it is mainly regulated by iNOS expression itself which synthesizes NO at nanomolar 

















Therefore, it would be reasonable to expect different effects emerging from nNOS versus 
iNOS inhibition. 
Despite the lack of effect of aminoguanidine upon total BDNF levels, we observed 
that repeated treatment increased pTRKB in dPAG. The ability of AMG treatment to 
upregulate pTRK in the dPAG was associated with its effectiveness upon the behavioral 
response in the ETM. Moreover, the blockade of AMG-induced TRKB signaling in the dPAG 
by k252a prevented the behavioral effects of AMG on escape latency. Similarly, this 
parameter was affected by systemic imipramine administration or locally injected BDNF. 
These effects were also blocked by intra-dPAG administration of k252a (Casarotto et al., 
2015).  
Taken together our data suggests that AMG exerts its panicolytic-like effect through 
an increase in pTRKB levels in the dPAG. It is still unclear how NO could modulate the 
activation of BDNF receptor, but it is plausible to consider that NO regulates local BDNF 
release in dPAG without changing its total levels. Accordingly, Canossa and co-workers 
(Canossa et al., 2002) showed that NOS inhibition increased BDNF release in cell culture 
of hippocampal neurons. Another intriguing possibility is a direct modulation of TRKB 
function by NO, through nitration and/or nitrosylation. Using an algorithm to analyze putative 
sites for nitration or nitrosylation [developed by (Xue et al., 2010; Liu et al., 2011)] in TRK 
receptors, we reported previously that TRKB displays sites with high probability for nitration 
of tyrosine residues (Biojone et al., 2015). Both mouse and rat mature TRKB receptors are 
potential targets for nitration at Y90, Y342 and Y816 residues. Interestingly, the Y816 
residue is also a well-known target of phosphorylation following TRKB activation either by 
BDNF or antidepressant drugs, which recruits PLC-gamma pathway (Huang and Reichardt, 
2001). Functionally, there is no evidence describing changes in nitrated TRKB responses. 

















peroxynitrite, suggesting a competitive functional interaction between these two 
modifications (Spear et al., 2002). Therefore, inhibiting the production of NO and putatively 
reducing the probability of TRKB nitration, could facilitate BDNF effect on TRKB receptor in 
the dPAG, leading to the observed panicolytic-like effect. This is an interesting hypothesis 
to explain nitric oxide effects on TRKB phosphorylation, which remains to be explored in 
future investigation.  
Overall our study shows that inhibition of physiological levels of nitric oxide modulates 
TRKB receptor phosphorylation in dPAG. Inhibition of nitric oxide production triggers TRKB 
activation thus inducing panicolityc-like response. Therefore, our study suggests that 
imbalanced nitric oxide production and TRKB signaling in dPAG could play a critical role in 
the pathogenesis of Panic Disorder. 
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 NOS inhibitor aminoguanidine induces panicolytic-like effect  
 Aminoguanidine treatment increases phosphorylation of TRKB receptor in dPAG  
 Blockade of TRKB receptors in dPAG abolishes aminoguanidine panicolytic-like effect  
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